Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double‐blind, placebo‐controlled, phase 3 trial-Reference-Cited by-同舟云学术

Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double‐blind, placebo‐controlled, phase 3 trial

Published:2021-01-31 Issue:5 Volume:23 Page:1111-1120
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Lu Juming¹,Fu Liujun²,Li Yan³,Geng Jianlin⁴,Qin Li⁵,Li Ping⁶,Zheng Hailong⁷,Sun Zilin⁸,Li Yanbing⁹^ORCID,Zhang Lihui¹⁰,Sun Yadong¹¹,Chen Daoxiong¹²,Qin Guijun¹³^ORCID,Lu Weiping¹⁴^ORCID,Guo Yushan¹⁵,Zhang Yuwei¹⁶,Liu Haiyan¹⁷,Zhang Tao¹⁷,Zou Jianjun¹⁷

Affiliation:

1. Department of Endocrinology Chinese PLA General Hospital Beijing China

2. Department of Endocrinology The First Affiliated Hospital of Henan University of Science and Technology Luoyang China

3. Department of Endocrinology Chongqing Sanxia Central Hospital Chongqing China

4. Department of Endocrinology Harrison International Peace Hospital Hengshui China

5. Department of Endocrinology Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

6. Department of Endocrinology Yuncheng Central Hospital Yuncheng China

7. Department of Endocrinology The First Affiliated Hospital of Hainan Medical University Haikou China

8. Department of Endocrinology Zhongda Hospital Affiliated to Southeast University Nanjing China

9. Department of Endocrinology The First Affiliated Hospital of Sun Yat‐sen University Guangzhou China

10. Department of Endocrinology The Second Hospital of Hebei Medical University Shijiazhuang China

11. Department of Endocrinology Jilin Province People's Hospital Changchun China

12. Department of Endocrinology Hainan General Hospital Haikou China

13. Department of Endocrinology The First Affiliated Hospital of Zhengzhou University Zhengzhou China

14. Department of Endocrinology The First Affiliated Huai'an Hospital of Nanjing Medical University Huai'an China

15. Department of Endocrinology The Affiliated Hospital of Beihua University Jilin China

16. Department of Endocrinology West China Hospital of Sichuan University Chengdu China

17. Jiangsu Hengrui Medicine Co. Ltd Shanghai China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14314

Reference26 articles.

1. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study

2. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

3. Understanding and overcoming metformin gastrointestinal intolerance

4. Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes;Journal of Diabetes Investigation;2024-09-10

2. Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial;Diabetes, Obesity and Metabolism;2024-04-15

3. Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry;2024-04

4. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems—A Literature Review;International Journal of Molecular Sciences;2024-02-06

5. Comparative safety of different recommended doses of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials;Frontiers in Endocrinology;2023-11-10